Agenus Inc.
NASDAQ:AGENBiotechnology
-$0.01 today
- Market cap
- $289.58M
- Beta
- 1.54
- P/E (TTM)
- 1.7
- EPS (TTM)
- $1.70
Volume 0.88M
Average 0.82M
AGEN EBITDA Margin
EBITDA as a percentage of revenue.
Agenus Inc.NASDAQ: AGEN
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to 161.5%
EBITDA Margin was 161.5% in Q1 FY2026, up 204.6 pp from a year earlier. On a trailing-twelve-month basis it was 102.6%, up 184.0 pp year over year. Over 3 fiscal years it widened by 219.6 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 2 analysts of 97.2% for the fiscal year ending Dec 2026, up from 54.5% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 161.5%+143.9 pp QoQ
- Last fiscal yearDec 2025
- 54.5%+152.4 pp YoY
- LTMMar 2026
- 102.6%+184.0 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 54.5%
- Year-over-year change
- +152.4pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 54.5% | +152.4pp |
| FY2024 | 2024-12-31 | -97.9% | -4.6pp |
| FY2023 | 2023-12-31 | -93.4% | +71.8pp |
| FY2022 | 2022-12-31 | -165.1% | -179.9pp |
| FY2021 | 2021-12-31 | 14.8% | — |
EBITDA Margin vs competitors
How AGEN compares with its peers on the latest reported figures
- AGEN's LTM Mar 2026 EBITDA Margin of 102.6% is the highest of the 5 companies compared; the peer median is -1366.5%.
- Its year-over-year change of +184.0 pp is the highest of 5, against a peer median of -674.2 pp.
- Over three fiscal years its change of +219.6 pp compares with a peer median of -1008.7 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 102.6% | +184.0 pp | +219.6 pp | |
| LTM Mar 2026 | -427.9% | +95.5 pp | +175.4 pp | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | -874.0% | -638.6 pp | -384.3 pp |
| LTM Mar 2026 | -1859.1% | -709.8 pp | -1633.0 pp | |
| FY2025 | -125425.9% | -77690.7 pp | -122786.1 pp | |
TTRXTurn Therapeutics Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding AGEN) | -1366.5% | -674.2 pp | -1008.7 pp | |
Competitors are the stored peer set for AGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 295.67M | 98.02M | 156.31M | 103.46M | 114.2M |
| Cost of Revenue | 182.08M | 197.26M | 237.68M | 156.01M | 80.36M |
| Gross Profit | 113.59M | (99.24M) | (81.37M) | (52.55M) | 33.84M |
| Gross Margin | 38.4% | -101.2% | -52.1% | -50.8% | 29.6% |
| Research & Development | 178.61M | 0 | 234.57M | 155.53M | 0 |
| Selling, General & Admin | 76.36M | 81.01M | 78.74M | 71.88M | 54.39M |
| Operating Expenses | 87.84M | 80.19M | 78.18M | 67.92M | 54.39M |
| Depreciation & Amortization | 6.79M | 6.95M | 13.59M | 13.34M | 10M |
| EBITDA | 43.78M | (161.85M) | (145.92M) | (101.3M) | 62.19M |
| EBITDA Margin | 14.8% | -165.1% | -93.4% | -97.9% | 54.5% |
| Operating Income | 25.75M | (179.43M) | (159.55M) | (120.48M) | (20.56M) |
| Operating Margin | 8.7% | -183.0% | -102.1% | -116.4% | -18.0% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 65.72M | 61.86M | 97.93M | 117.63M | 55.27M |
| Other Income / Expenses | (54.47M) | (51.23M) | (97.89M) | (111.8M) | 17.47M |
| Income Before Tax | (28.72M) | (230.66M) | (257.44M) | (232.27M) | (3.08M) |
| Pre-Tax Margin | -9.7% | -235.3% | -164.7% | -224.5% | -2.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (23.93M) | (220.07M) | (245.76M) | (227.21M) | 115K |
| Net Margin | -8.1% | -224.5% | -157.2% | -219.6% | 0.1% |
| EPS (Basic) | (2.11) | (15.64) | (13.75) | (10.59) | (0.00) |
| EPS (Diluted) | (2.11) | (15.64) | (13.75) | (10.59) | (0.00) |
| Weighted Avg Shares | 11.45M | 14.09M | 17.89M | 21.47M | 29.73M |
| Weighted Avg Shares (Diluted) | 11.45M | 14.09M | 17.89M | 21.47M | 29.73M |
Agenus Inc.
NASDAQ:AGEN
Intrinsic Alpha fair value
Locked
Current Price
$6.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.